About Us
To deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.
Our Values
Moderna people hold a deep sense of responsibility for each other, patients, the environment and our local communities. Our people live our Values every day.
Meet the United Kingdom leadership team
We’re making biotech history
Messenger RNA is not new technology, but we are discovering new ways to use it to treat and prevent illnesses and diseases. Since our founding in 2010, we have worked to build the industry's leading mRNA technology platform.
Our big moments
Moderna incorporates
Moderna’s name combines the words "modified" and "RNA", which happens to contain the word "modern.”
Operations started
Moderna begins research into the production of mRNA medicines. Stéphane Bancel joins as founding CEO.
First human dose of flu vaccine
Moderna initiates first-in-human dose of an mRNA vaccine (mRNA-1440), an H10N8 flu vaccine candidate.
First human dose of multivalent vaccine
Moderna initiates first-in-human dosing for mRNA-1653, a combination vaccine with the potential to protect against more than one disease – human metapneumovirus (hMPV virus) and parainfluenza virus.
First antibody encoded by mRNA
Moderna announces dosing of the first antibody encoded by mRNA in a clinical trial
UK Medicines and Healthcare products Regulatory Agency (MHRA)
MHRA begins rolling review of Moderna’s mRNA vaccine against COVID-19.¹
Supply agreement
Moderna announces supply agreement with UK Government for COVID-19 mRNA vaccine if approved for use.²
UK MHRA approval
MHRA authorises the use of Moderna’s mRNA vaccine against COVID-19.³
COVAX
Moderna announces European Union and European Economic Area Countries to donate more than 70 million doses of Moderna COVID-19 Vaccine to COVAX in 2021 to help end COVID-19 pandemic in low income countries.⁴
Supply agreement
Moderna and UK Government agree additional 60 million doses of mRNA COVID-19 vaccine for 2022-23.⁵
UK expansion
New headquarters open in London, Victoria.
Bivalent booster
Moderna announces Omicron-containing bivalent booster candidate mRNA-1273.214.⁶
¹United Kingdom Medicines and Healthcare products Regulatory Agency Authorizes Use of COVID-19 Vaccine Moderna. Businesswire 2021. Available at: https://www.businesswire.com/news/home/20210108005274/en/United-Kingdom-Medicines-and-Healthcare-products-Regulatory-Agency-Authorizes-Use-of-COVID-19-Vaccine-Moderna
²Moderna Announces Supply Agreement with United Kingdom Government to Supply mRNA Vaccine Against COVID-19 (mRNA-1273) if Approved for Use. Available at: Moderna Announces Supply Agreement with United Kingdom Government to Supply mRNA Vaccine Against COVID-19 (mRNA-1273) if Approved for Use | Business Wire
³United Kingdom Medicines and Healthcare products Regulatory Agency Authorizes Use of COVID-19 Vaccine Moderna, Available at:United Kingdom Medicines and Healthcare products Regulatory Agency Authorizes Use of COVID-19 Vaccine Moderna | Business Wire
⁴Moderna Announces European Union and European Economic Area Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to COVAX in 2021 to Help End COVID-19 Pandemic in Low Income Countries. Available at: Moderna Announces European Union and European Economic Area Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to COVAX in 2021 to Help End COVID-19 Pandemic in Low Income Countries | Business Wire
⁵Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023. Available at:Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023 | Business Wire
⁶Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron. Available at: Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron (modernatx.com)